Table 5 Comparison of the hospital and follow-up events between patients who had emergency left main (LM) and non-emergency LM revascularization
|  | Overall, n = 2138 | Emergent LM revascularization n = 460 (21.5%) | P-Value | Non-emergent LM revascularization n = 1678 (78.5%) | P Value | ||
|---|---|---|---|---|---|---|---|
PCI (n = 264) | CABG (n = 196) | PCI (n = 958) | CABG (n = 720) | ||||
In-hospital events | |||||||
 Cardiac death, n (%) | 81 (3.8%) | 36 (13.64%) | 23 (11.73%) | 0.546 | 3 (0.31%) | 19 (2.64%) |  < 0.001 |
 Non-cardiac death, n (%) | 24 (1.1%) | 4 (1.52%) | 3 (1.53%) |  > 0.99 | 3 (0.31%) | 14 (1.94%) | 0.001 |
 Myocardial infarction, n (%) | 73 (3.4%) | 15 (5.68%) | 20 (10.20%) | 0.070 | 3 (0.31%) | 35 (4.86%) |  < 0.001 |
 Target lesion revascularization, n (%) | 11 (0.5%) | 3 (1.14%) | 1 (0.51%) | 0.640 | 2 (0.21%) | 5 (0.69%) | 0.147 |
 Target vessel revascularization, n (%) | 15 (0.7%) | 5 (1.89%) | 0 | 0.075 | 2 (0.21%) | 8 (1.11%) | 0.023 |
 Cerebrovascular events, n (%) | 48 (2.2%) | 12 (4.55%) | 13 (6.63%) | 0.329 | 7 (0.73%) | 16 (2.22%) | 0.009 |
 MACCE, n (%) | 125 (5.8%) | 38 (14.39%) | 28 (14.29%) | 0.974 | 16 (1.67%) | 43 (5.97%) |  < 0.001 |
 Congestive heart failure, n (%) | 89 (4.2%) | 17 (6.44%) | 32 (16.33%) | 0.001 | 32 (3.34%) | 8 (1.11%) | 0.003 |
 Major bleeding, n (%) | 313 (14.6%) | 39 (14.77%) | 34 (17.35%) | 0.455 | 125 (13.06%) | 115 (15.97%) | 0.092 |
 Minor bleeding, n (%) | 157 (7.3%) | 17 (6.44%) | 18 (9.18%) | 0.272 | 50 (5.22%) | 72 (10%) |  < 0.001 |
 Total mortality, n (%) | 105 (4.9%) | 40 (15.15%) | 26 (13.27%) | 0.568 | 6 (0.63%) | 33 (4.58%) |  < 0.001 |
 Duration of hospital stay, median (IQR) (Days) | 7 (3–12) | 5 (3–9) | 13 (9–17) |  < 0.001 | 3 (0–5) | 11 (8–15) |  < 0.001 |
Follow-up events | |||||||
 Cardiac death, n (%) | 14 (0.7%) | 5 (2.59%) | 2 (1.23%) | 0.889 | 3 (0.33%) | 4 (0.60%) | 0.524 |
 Non-cardiac death, n (%) | 25 (1.3%) | 2 (1.04%) | 0 | 0.237 | 10 (1.09%) | 13 (1.94%) | 0.043 |
 Myocardial infarction, n (%) | 50 (2.6%) | 3 (1.63%) | 10 (6.29%) | 0.005 | 21 (2.33%) | 16 (2.41%) | 0.665 |
 Target lesion revascularization, n (%) | 52 (2.72%) | 8 (4.35%) | 8 (5.03%) | 0.371 | 27 (2.99%) | 9 (1.35%) | 0.141 |
 Target vessel revascularization, n (%) | 57 (2.98%) | 4 (2.17%) | 8 (5.03%) | 0.046 | 27 (2.99%) | 18 (2.71%) | 0.936 |
 Cerebrovascular events, n (%) | 29 (1.64%) | 4 (2.22%) | 4 (2.96%) | 0.636 | 11 (1.25%) | 10 (1.76%) | 0.465 |
 MACCE, n (%) | 108 (6.1%) | 15 (8.33%) | 16 (11.85%) | 0.099 | 48 (5.45%) | 29 (5.09%) | 0.955 |
 Congestive heart failure, n (%) | 415 (19.4%) | 83 (31.44%) | 24 (12.24%) | 0.008 | 212 (22.13%) | 96 (13.33%) |  < 0.001 |
 Major bleeding, n (%) | 7 (0.4%) | 0 | 0 |  | 5 (0.57%) | 2 (0.35%) | 0.614 |
 Minor bleeding, n (%) | 31 (1.76%) | 5 (2.78%) | 4 (2.96%) | 0.685 | 11 (1.25%) | 11 (1.93%) | 0.322 |
 Total mortality, n (%) | 39 (2.0%) | 7 (3.63%) | 2 (1.23%) | 0.470 | 13 (1.41%) | 17 (2.54%) | 0.036 |
 Median follow-up time (IQR) (months) | 20 (10–37) | 20 (13–31) | 12 (3–33) | 0.002 | 21 (12–39) | 19 (9–37) | 0.009 |